Author Correction: Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans

In the original version of this Article, there was an error in the calculations of the areas under the curve (AUCs), which systematically overestimated the AUCs for the three methods of oxytocin administration. As a result, Fig. 5, Fig. 6B and C, and Supplementary Table 2 and Supplementary Table 3, and a part of the Results section, contained errors. Repeating all analyses with the correctly calculated AUCs did not change the pattern of results or the conclusions of the analyses. Below are the revised versions of all Results, Figures and Tables where the error in the AUC calculations could have affected the results.


Supplementary Figure 2 -Subjective ratings of alertness and excitement
We tested for treatment, time interval and treatment x time-interval effects on subjective ratings of alertness and excitement, collected at 3 different time-points during the scanning period, in a repeated measures analysis of variance. In panels A and B, we present the results for alertness and excitement, respectively. Anchors -Alertness: 0 -Alert; 100 -Drowsy; Excitement: 0 -Calm; 100 -Excited. Data are presented as mean ± 1 standard error of the mean (SEM). Statistical significance was set to p<0.05 (two-tailed). Error bars correspond to SEM. IN -Spray; IV -Intravenous; NB -Nebulizer; PL -Placebo. Source data are provided as a Source Data file.

Supplementary Figure 3 -Correlation between global cerebral blood flow and subjective ratings.
To investigate if the changes in the subjective ratings we identified are associated with changes in global cerebral blood flow (CBF) across time, we used within-group pooled Pearson correlation coefficients (r) to examine self-ratings of alertness and excitement could predict global CBF over time. In panel A, we present Global CBF vs Alertness; and in panel B, Global CBF vs Excitement. Statistical significance was set to p<0.05 (two-tailed). IN -Spray; IV -Intravenous; NB -Nebulizer; PL -Placebo.

Supplementary Figure 4 -Human whole-brain distribution of OT-related receptors.
Panel A refer to OXTR and Panel B to V1aR. Scale refers to spatial whole-brain distribution of the predicted mRNA expression intensity as determined by Gryglewski et al.1 using the Allen Brain Atlas data; these maps were generated by applying a variogram model in Gaussian process regression allowing to infer gene expression with high resolution and across the whole brain; the original maps can be freely downloaded from http://www.meduniwien.ac.at/neuroimaging/mRNA.html)

Supplementary Table 1 -Effects of treatment, time-interval and treatment x time-interval on global cerebral blood flow and subjective ratings.
Detailed statistics for each effect. The effects of treatment, time-interval and treatment x time-interval were tested using repeated measures 2-way ANOVA. Statistical significance was set to p<0.05 (two-tailed). * highlights statistically significant effects; CBF -Cerebral blood flow. Source data are provided as a Source Data file.

Supplementary Table 3 -Spearman correlations between drug-induced changes in rCBF and variations of the concentration of oxytocin in the plasma post-dosing.
We present values of the spearman correlation coefficient (r), with respective 95% confidence intervals (CI) for all clusters identified as significant in the comparisons drug vs placebo for the three treatment methods of administration. Statistical significance was set to p<0.05 (two-tailed) and is highlighted with a star symbol.  Table 4 -Percentage of observations satisfying quality control criteria for the pulse plethysmography analysis. Following current recommendations for heart rate data processing and analysis, if more than 5% of the beats required correction, then we decided to exclude these periods of observation. In some rare cases where artefacts could not be corrected, we only included the data if at least 5 min of acquisition free of artefacts could be analysed. In this table, we present the percentage of total data available satisfying our quality control criteria for each treatment method of administration and time-interval, so the reader can appreciate the amount of data effectively used in the final analysis. Supplementary Table 5 -Oxytocin did not affect heart rate or heart rate variability. We determined time-interval, treatment, and treatment x time-interval effects on a set of time domain (heart-rate (HR) and the root mean square of the successive differences (RMSSD), frequency domain (low (LF) and high (HF) frequencies spectral powers and high/low frequency spectral power ratio (HF/LF)) and non-linear (Approximate entropy (ApEn), the SD1 and SD2 lines from the Poincare Plot and the detrended fluctuation scaling exponents DFAα1 and DFAα2) analysis measures of heart rate variability. We used a repeated measures two-way analysis of variance, using subjects, treatment and time as factors, and the Greenhouse-Geisser correction against violations of sphericity. Statistical significance was set to p<0.05. We contained the false-discovery rate (FDR) at α=0.05 using the Benjamini-Hochberg procedure.